News
-
Coronavirus: EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab)
-
Coronavirus: EMA started evaluating an application to extend the use of Veklury (remdesivir)
-
Coronavirus: Reports of delayed local reactions after vaccination
-
Federal Administrative Court, Interim Order B-3340/2020 of 15 February 2021
-
Federal Administrative Court, Decision C-637/2018 of 15 February 2021
-
Federal Administrative Court, Decision C-7133/2017 of 16 February 2021
-
Swissmedic permanently involved in Project Orbis
-
Federal Administrative Court, Decision B-1374/2020 of 21 December 2020
-
Federal Administrative Court, Decision C-2887/2019 of 26 January 2021
-
Federal Administrative Court, Decision C-2818/2019 of 4 February 2021
-
Coronavirus: Federal Council plans first cautious steps to reopen from 1 March
-
COVID-19: EMA is piloting a new ‘OPEN’ initiative
-
COVID-19: Reports of suspected adverse reactions to the COVID-19 vaccines in Switzerland
-
Federal Supreme Court, Decision 2F_29/2020 of 22 January 2021
-
Federal Supreme Court, Decision 4A_432/2020 of 16 December 2020
-
COVID-19 vaccine: Federal Government signs three more contracts
-
COVID-19 vaccine: Federal Government to cover vaccination costs for further groups
-
COVID-19 vaccine: Swissmedic requests additional data on the vaccine from AstraZeneca
-
COVID-19 vaccine: EMA recommends AstraZeneca's COVID-19 vaccine for approval in the EU
-
Federal Supreme Court, Decision 9C_511/2020 of 13 January 2021
-
Coronavirus: Federal government to cover costs of tests for persons without symptoms and modify quarantine rules